Mareque M, Montesinos P, Font P, Guinea JM, de la Fuente A, Soto J, . . . Sierra J. (2021). Cost-Effectiveness Analysis of Gemtuzumab Ozogamicin for First-Line Treatment of Patients with Cd-33 Positive Acute Myeloid Leukaemia in Spain [Corrigendum]. Dove Medical Press.
Chicago Style (17th ed.) CitationMareque M, et al. Cost-Effectiveness Analysis of Gemtuzumab Ozogamicin for First-Line Treatment of Patients with Cd-33 Positive Acute Myeloid Leukaemia in Spain [Corrigendum]. Dove Medical Press, 2021.
MLA (9th ed.) CitationMareque M, et al. Cost-Effectiveness Analysis of Gemtuzumab Ozogamicin for First-Line Treatment of Patients with Cd-33 Positive Acute Myeloid Leukaemia in Spain [Corrigendum]. Dove Medical Press, 2021.
Warning: These citations may not always be 100% accurate.